Sunitinib: clinical application and production overview of multi-target tyrosine kinase inhibitors

Sunitinib is an oral multi-target tyrosine kinase inhibitor mainly used to treat renal cell carcinoma, gastrointestinal stromal tumors and pancreatic neuroendocrine tumors. This article will start from four aspects: drug mechanism, indications, clinical efficacy and manufacturer, focusing on analyzing its targeted therapy value and market application status. In terms of primary and secondary structure, we first introduce the basic information of the drug, then go into the clinical data, and finally sort out the manufacturing companies to ensure a clear content hierarchy.

Drug mechanism and core indications

Sunitinib blocks tumor angiogenesis and cell proliferation by inhibiting targets such as vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR). Its core indications include:Advanced renal cell carcinoma (first-line treatment),Imatinib-resistant gastrointestinal stromal tumor (GIST)andAdvanced pancreatic neuroendocrine tumors. Clinical studies have shown that sunitinib can significantly prolong the progression-free survival (PFS) of patients, and some patients have significant benefits in overall survival (OS).

Clinical efficacy and key research data

A phase III clinical trial (NCT00098657) showed that sunitinib had an objective response rate (ORR) of 31% and a median PFS of 11 months in the treatment of advanced renal cancer, which was superior to traditional interferon therapy. In the treatment of GIST, the disease control rate exceeds 50%. Common adverse reactions include fatigue, hypertension, hand-foot syndrome, etc., most of which can be managed through dose adjustment. The table below summarizes key data:

Production companies and market status

Origin of sunitinibPfizerResearch and development, trade nameSutent. At present, there are generic drugs on the market in China, and the main manufacturers includeIt's sunny,Qilu PharmaceuticalWait. Original drugs and generic drugs have the same active ingredients, but there may be differences in excipient processes. Patients need to choose under the guidance of a doctor and pay attention to the medical insurance reimbursement policy (for example, Sutent has been included in some national medical insurance directories).

Summary and Outlook

As the first approved multi-target anti-tumor drug, sunitinib provides an important treatment option for advanced renal cancer and other diseases. Its efficacy and safety data are mature, but adverse reactions require individualized management. In the future, the exploration of combined immunotherapy or new targeted drugs may further expand its application scenarios. Patients should strictly follow medical instructions when taking medication and monitor relevant indicators regularly.

Quote sources:
1. U.S. FDA drug package insert (Sutent®)
2. "New England Journal of Medicine": Motzer RJ et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma.
3. China National Medical Products Administration (NMPA) generic drug approval information
4. Public disclosure of information by manufacturers (official websites of Pfizer and Chia Tai Tianqing)